UA87822C2 - Похідні нафтилену як інгібітори цитохрому p450 - Google Patents

Похідні нафтилену як інгібітори цитохрому p450

Info

Publication number
UA87822C2
UA87822C2 UAA200601312A UAA200601312A UA87822C2 UA 87822 C2 UA87822 C2 UA 87822C2 UA A200601312 A UAA200601312 A UA A200601312A UA A200601312 A UAA200601312 A UA A200601312A UA 87822 C2 UA87822 C2 UA 87822C2
Authority
UA
Ukraine
Prior art keywords
cytochrome
inhibitors
treatment
naphthylene
derivatives
Prior art date
Application number
UAA200601312A
Other languages
English (en)
Russian (ru)
Inventor
Ванесса Смит
Энтони Найгро
Марк Малвихилл
Кара Сесарио
Патришия Энн Бек
Арлиндо Лукас Кастелано
Original Assignee
Оси Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оси Фармасьютикалз, Инк. filed Critical Оси Фармасьютикалз, Инк.
Publication of UA87822C2 publication Critical patent/UA87822C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
UAA200601312A 2003-07-10 2004-12-07 Похідні нафтилену як інгібітори цитохрому p450 UA87822C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10

Publications (1)

Publication Number Publication Date
UA87822C2 true UA87822C2 (uk) 2009-08-25

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200601312A UA87822C2 (uk) 2003-07-10 2004-12-07 Похідні нафтилену як інгібітори цитохрому p450

Country Status (15)

Country Link
EP (1) EP1654236A1 (uk)
JP (1) JP4832295B2 (uk)
KR (1) KR20060052799A (uk)
CN (1) CN1819996B (uk)
AU (1) AU2004257257B2 (uk)
BR (1) BRPI0412424A (uk)
CA (1) CA2532078A1 (uk)
IL (1) IL172812A0 (uk)
IS (1) IS8223A (uk)
MX (1) MXPA06000401A (uk)
NO (1) NO20060114L (uk)
RU (1) RU2363696C2 (uk)
SG (1) SG144941A1 (uk)
UA (1) UA87822C2 (uk)
WO (1) WO2005007631A1 (uk)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058301A1 (en) * 2003-12-17 2005-06-30 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
WO2011153192A2 (en) 2010-06-01 2011-12-08 Angion Biomedica Corp. Cytochrome p450 inhibitors and uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
KR20180039185A (ko) * 2010-11-13 2018-04-17 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
CN103328452A (zh) * 2010-12-13 2013-09-25 威尔金制药有限公司 金属酶抑制剂化合物
CN102586187A (zh) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 一种中性粒细胞体外保存方法及培养基
WO2014015137A2 (en) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
US9988374B2 (en) 2014-08-11 2018-06-05 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
CN104523967B (zh) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 一种柏艾胶囊作为cyp酶抑制剂的应用
JP2018501279A (ja) 2014-12-31 2018-01-18 アンギオン バイオメディカ コーポレイション 疾患を治療するための方法及び薬剤
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
KR102628073B1 (ko) 2017-01-10 2024-01-22 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
UY37556A (es) 2017-01-10 2018-07-31 Bayer Ag Derivados heterocíclicos como pesticidas

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (uk) * 1960-05-04
NL131915C (uk) * 1966-07-27
DE3508903A1 (de) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylmethylnaphtylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3628545A1 (de) * 1985-09-23 1987-04-23 Hoechst Ag Arylmethylazole und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
WO1994008973A1 (en) * 1992-10-21 1994-04-28 Sankyo Company, Limited Azole compound
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
CA2328973A1 (en) * 1998-04-23 1999-10-28 Akio Ojida Naphthalene derivatives, their production and use
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 1−置換−1−(1h−イミダゾール−4−イル)メタノール類

Also Published As

Publication number Publication date
AU2004257257B2 (en) 2011-05-12
IS8223A (is) 2006-01-10
RU2006103996A (ru) 2006-07-10
AU2004257257A1 (en) 2005-01-27
NO20060114L (no) 2006-02-09
CA2532078A1 (en) 2005-01-27
SG144941A1 (en) 2008-08-28
BRPI0412424A (pt) 2006-09-05
CN1819996B (zh) 2010-10-27
RU2363696C2 (ru) 2009-08-10
JP4832295B2 (ja) 2011-12-07
EP1654236A1 (en) 2006-05-10
JP2007523866A (ja) 2007-08-23
CN1819996A (zh) 2006-08-16
WO2005007631A1 (en) 2005-01-27
KR20060052799A (ko) 2006-05-19
MXPA06000401A (es) 2006-03-17
IL172812A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
NO20060114L (no) Naftylenderivater som cytokrom P450-inhibitorer
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
TW200728307A (en) Novel spirochromanone derivatives
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
NZ598242A (en) Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
TW200612958A (en) Substituted imidazole derivatives
AU2003297291A1 (en) Substituted arylcyclopropylacetamides as glucokinase activators
BR0316583A (pt) Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
IL179607A0 (en) Indoles useful in the treatment of inflammation
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
WO2007084728A3 (en) 2-imino-benzimidazoles
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
TW200613289A (en) Prodrugs of hiv protease inhibitors
UA97256C2 (uk) Заміщені піразоли та триазоли як інгібітори кбв (кінезин-білок веретена)
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
HK1111168A1 (en) A PROCESS FOR THE PREPARATION OF 17-HYDROXY-6 ß,7ß,15 ß,16 ß - BISMETHYLENE-17a-PREGN-4-ENE-3-ONE-21-CARBOXYLIC ACID Y-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS
WO2004012663A3 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
DE602005011267D1 (de) Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors